爱科百发赴港IPO:年亏9163万,尚未产品商业化

格隆汇2021-07-06

上海爱科百发生物医药技术股份有限公司(以下简称“爱科百发”)向港交所递交上市招股说明书,美银、中信证券和华兴资本担任联席保荐人,德勤为其审计师。 自2014年成立以来,爱科百发共开展了8轮融资。在最新的C+轮融资中,2021年1月,公司引入高瓴创投、TPG联合领投,万容红土、瑞华投资、燕园姚商等8家投资机构参与投资,融资后公司估值达到38.7亿元。 IPO前,公司股权架构方面,Jim Zhen ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
1